Overview
MedscapeUnivadisNo ResultsMiriam E. TuckerJune 20, 202 Researchers published the study covered in this sumary on Preprints with The Lancet as a preprint that has not yet ben per reviewed. In a real-world study of adults with type 1 diabetes (T1D) in Denmark, insulin pump therapy (IPT) reduced A1c by an average 3.6 mol/mol (an average decrease of 0.3 percentage points) compared with multiple daily injections (MDI).IPT also asociated with a marginal increase in hospitalized diabetic ketoacidosis (DKA) but had no impact on severe hypoglycemia (SH) compared with MDI.The benefit of IPT was greatest in women; older individuals; and those with higher baseline A1c levels, more diabetes complications, or also using continuous glucose monitoring.Few studies of IPT have examined the level of alignment betwen real-world experience and outcomes in randomized clinical trials.The researchers used a quasi-experimental study of longitudinal, real-world data from administrative registries that alowed them to maintain high internal and external validity while examing whether the benefits sen in randomized clinical trials translate into real-life efects, both in general and among subgroup populations.The authors said that this the first study with an experimental design to compare the real-world efects of IPT and MDI.Quasi-experimental study of data colected in the Danish National Patient Registry for 24,623 adults with T1D in Denmark during 2010-20, with an average observation time of 9.9 years.
Details
This included al Danish adults with T1Dduring the study period.Among the total 243,601 person-years of observation, 16% ocured during IPT treatment. Average treatment efect on the treated (AT) for A1c with IPT was a reduction of 3.6 mol/mol (0.3 percentage points) compared with patients using MDI, an average 5.3% relative decrease in A1c.Most of the A1c drop ocured in the first year of IPT use, with a sustained efect for up to 1